Denali Group

Trian Partners is a financial investment firm based in New York, NY, specializing in strategic investments and shareholder activism. With a focus on creating long-term value for its clients, Trian Partners leverages its expertise in corporate governance and operational efficiency to drive positive change within the companies it invests in. Generated from their business information

General Information About Since our founding in 2003, Cowen Group has established itself as the top eDiscovery staffing and management consulting firm. Our renowned ability to deliver the most qualified talent available while providing strategic staffing and management advice is built upon a foundation of deep marketplace knowledge, extensive personal relationships, and a relentless commitment to excellence and results. Focused exclusively on recruiting and staffing in eDiscovery and legal technology, we have exclusive access to jobs at elite organizations, and know how to help you hire, train, and retain top talent. Executives at more than 175 major law firms and over 300 major corporations regularly turn to us for advice, guidance, and insight to successfully deal with the challenges posed by people, process, and technology in today's litigation support and eDiscovery community. Regular nationwide events and cutting edge market research strengthen and build upon these valuable ties, which we can then leverage for our candidates. Drawing upon our extensive market research, clients are able to track and exploit strategic trends in compensation, workload, organization structure, technology, and management. Our series of nationwide roundtable discussions provides a forum to explore these trends with peers and colleagues within the eDiscovery and legal technology industries. The Cowen Group's dedication to our philosophy, "first, be of service, " drives us to create transparency in the industry, to leverage our knowledge and experience for the community, and to help professionals develop their careers. How can we be of service to you?

New Leaf Venture Partners' objectives with each investment are to back a strong, entrepreneurial management team, to provide appropriate financial resources, to help build a great company, and to create exceptional equity value. We are active investors and almost always serve as directors of our portfolio companies, who can draw upon perspectives and experiences of the entire NLV investment team and its network of successful scientists, clinicians, operating executives and entrepreneurs. We assist in building management teams, guiding corporate strategy, providing input to operating plans, and in making decisions about optimal paths for future financings and exits. As conditions evolve, NLV Partners team continually refines its differentiated strategy in healthcare investing. Both of NLV's latest funds, New Leaf Ventures I and New Leaf Ventures II, focus on taking leadership positions in: Biopharmaceuticals - NLV has an in-depth understanding of therapeutic targets and modalities, the drug R&D process, clinical trial design, regulatory requirements, and pharmaceutical commercial activities. NLV's extensive medical, clinical development, commercial and financial experience helps companies navigate the challenging path to regulatory approval and commercialization as stand-alone companies or through value-added strategic partnerships. NLV invests in companies at all stages in this sector, but looks at the level of risk, costs, and timelines to build real value in the underlying program (s) in determining if an investment fits our strategy. NLV has been particularly active in starting and investing in companies that been formed around the spin out of programs from larger pharmaceutical and biotech companies. Medical devices - NLV works closely with its network of entrepreneurs and scientific and medical founders to identify investment opportunities around promising technologies targeting areas of high unmet medical need and large commercial potential. The current strategy is to focus on later stage opportunities to provide growth capital or the last round to profitability in which regulatory and reimbursement risks are minimal. NLV will invest in early stage companies when there are large established global markets and an opportunity to prove safety and effectiveness in a focused, cost effective program. NLV's investment team brings critical operating experience and the ability to evaluate the biological, engineering, regulatory, reimbursement and market risks most relevant to starting, growing, developing and exiting young or more mature companies in the medical devices sector.